134 related articles for article (PubMed ID: 20716255)
1. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study.
Judlin P; Liao Q; Liu Z; Reimnitz P; Hampel B; Arvis P
BJOG; 2010 Nov; 117(12):1475-84. PubMed ID: 20716255
[TBL] [Abstract][Full Text] [Related]
2. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial.
Aşicioğlu O; Gungorduk K; Ozdemir A; Ertas IE; Yildirim G; Sanci M; Ark C
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):116-21. PubMed ID: 23993130
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
Ross JD; Cronjé HS; Paszkowski T; Rakoczi I; Vildaite D; Kureishi A; Alefelder M; Arvis P; Reimnitz P;
Sex Transm Infect; 2006 Dec; 82(6):446-51. PubMed ID: 16723364
[TBL] [Abstract][Full Text] [Related]
4. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease.
Heystek M; Ross JD;
Int J STD AIDS; 2009 Oct; 20(10):690-5. PubMed ID: 19815913
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
[TBL] [Abstract][Full Text] [Related]
6. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease.
Boothby M; Page J; Pryor R; Ross JD
Int J STD AIDS; 2010 Mar; 21(3):195-7. PubMed ID: 20215625
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin: new indication. Do not use in gynaecological infections or other conditions.
Prescrire Int; 2009 Oct; 18(103):207. PubMed ID: 19882788
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
9. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
10. Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study.
Judlin P; Thiebaugeorges O
Eur J Obstet Gynecol Reprod Biol; 2009 Aug; 145(2):177-9. PubMed ID: 19467767
[TBL] [Abstract][Full Text] [Related]
11. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials.
Haggerty CL; Ness RB
Clin Infect Dis; 2007 Apr; 44(7):953-60. PubMed ID: 17342647
[TBL] [Abstract][Full Text] [Related]
12. Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases.
Chauny JV; Lorrot M; Prot-Labarthe S; De Lauzanne A; Doit C; Géréral T; Bourdon O
Pediatr Infect Dis J; 2012 Dec; 31(12):1309-11. PubMed ID: 22814964
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
[TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
Hadley JA; Mösges R; Desrosiers M; Haverstock D; van Veenhuyzen D; Herman-Gnjidic Z
Laryngoscope; 2010 May; 120(5):1057-62. PubMed ID: 20422704
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial.
Vehreschild JJ; Moritz G; Vehreschild MJ; Arenz D; Mahne M; Bredenfeld H; Chemnitz J; Klein F; Cremer B; Böll B; Kaul I; Wassmer G; Hallek M; Scheid C; Cornely OA
Int J Antimicrob Agents; 2012 Feb; 39(2):130-4. PubMed ID: 22169408
[TBL] [Abstract][Full Text] [Related]
16. Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.
Ewig S; Hecker H; Suttorp N; Marre R; Welte T;
J Infect; 2011 Mar; 62(3):218-25. PubMed ID: 21276814
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study.
De Waele JJ; Tellado JM; Alder J; Reimnitz P; Jensen M; Hampel B; Arvis P
Int J Antimicrob Agents; 2013 Jan; 41(1):57-64. PubMed ID: 23153963
[TBL] [Abstract][Full Text] [Related]
18. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Starakis I; Gogos CA; Bassaris H
Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
[TBL] [Abstract][Full Text] [Related]
19. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
20. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
